CoChat

Efficacy and safety of exenatide as add‐on therapy for patients with type 2 diabetes with an intensive insulin regimen: A randomized double‐blind trial

Joubert, Michael, Opigez, Victoria, Pavlikova, Barbora, Peyro Saint Paul, Laure, Jeandidier, Nathalie, Briant, Anaïs R., Parienti, Jean‐Jacques, Reznik, Yves · 2021 · Diabetes, Obesity and Metabolism
Cited by 13

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Aim: To assess the safety and efficacy of the short‐acting glucagon‐like peptide‐1 receptor agonist exenatide on a population of patients with type 2 diabetes (T2D) mostly treated with continuous subcutaneous insulin injection (CSII). Materials and Methods: A phase 2/3, multicentre, randomized, parallel‐group, double‐blind, placebo‐controlled, 6‐month trial was conducted. Patients were randomized to receive subcutaneous (SC) injections of exenatide (10 μg BID) or matched placebo. Results: A total of 46 patients with T2D and elevated HbA1c were randomized (42% of the planned sample size): exenatide (n = 28) and placebo (n = 18). CSII treatment was used by 75% and 89% of patients of the exenatide and placebo groups, respectively. At 6 months, the change in HbA1c was −0.62% ± 0.94% and 0.08% ± 0.81% in the exenatide and placebo groups, respectively (difference, −0.70%; 95% CI [−1.24%; −0.15%], P = .014); body weight and body mass index decreased in the exenatide group (−2.55 ± 3.25 kg and −1.00 ± 1.31 kg/m 2 ) and increased in the placebo group (1.29 ± 2.82 kg and 0.46 ± 1.16 kg/m 2 ) (observed difference, −3.85 and −1.45, respectively, both P < .001); the postdinner capillary blood glucose value was lower in the exenatide group compared with the placebo group (162.4 ± 80.5 vs. 259.1 ± 94.4 mg/dL, respectively; observed difference, −96.7, P < .01). Hypoglycaemic risk, quality of life and overall safety were not different between the groups, apart from the expected occurrence of digestive effects in the exenatide group. Conclusions: Although we failed to reach our planned sample size, the addition of exenatide treatment 10 μg BID SC in T2D patients with uncontrolled HbA1c despite an intensified insulin regimen, resulted in a significant reduction of HbA1c and body weight with a good overall safety profile and acceptance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.14225

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 13

Metadata

Authors
Joubert, M., Opigez, V., Pavlikova, B., Peyro Saint Paul, L., Jeandidier, N., Briant, A. R., Parienti, J., & Reznik, Y.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2020-10-30
Volume
23
Issue
2
Pages
374-381
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W3092124082
Cited by
13
References
5
FWCI
0.80
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.